|
1
|
Tao Z, Shi A, Lu C, Song T, Zhang Z and
Zhao J: Breast cancer: Epidemiology and etiology. Cell Biochem
Biophys. 72:333–338. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hoon Tan P, Ellis I, Allison K, Brogi E,
Fox SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, et al:
The 2019 WHO classification of tumours of the breast.
Histopathology. Feb 13–2020.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Emens LA: Breast cancer immunotherapy:
Facts and hopes. Clin Cancer Res. 24:511–520. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ge W, Jiang M, Zhang F, Ma Y, Wang H and
Xu Y: ZGRF1 is associated with poor prognosis in triple-negative
breast cancer and promotes cancer stemness based on bioinformatics.
Onco Targets Ther. 13:2843–2854. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aljohani AI, Joseph C, Kurozumi S,
Mohammed OJ, Miligy IM, Green AR and Rakha EA: Myxovirus resistance
1 (MX1) is an independent predictor of poor outcome in invasive
breast cancer. Breast Cancer Res Treat. 181:541–551. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou Z, Yao H and Hu H: Disrupting tumor
angiogenesis and ‘the hunger games’ for breast cancer. Adv Exp Med
Biol. 1026:171–195. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oike Y, Yasunaga K, Ito Y, Matsumoto S,
Maekawa H, Morisada T, Arai F, Nakagata N, Takeya M, Masuho Y and
Suda T: Angiopoietin-related growth factor (AGF) promotes epidermal
proliferation, remodeling, and regeneration. Proc Natl Acad Sci
USA. 100:9494–9499. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oike Y, Ito Y, Maekawa H, Morisada T,
Kubota Y, Akao M, Urano T, Yasunaga K and Suda T:
Angiopoietin-related growth factor (AGF) promotes angiogenesis.
Blood. 103:3760–3765. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carbone C, Piro G, Merz V, Simionato F,
Santoro R, Zecchetto C, Tortora G and Melisi D: Angiopoietin-like
proteins in angiogenesis, inflammation and cancer. Int J Mol Sci.
19:4312018. View Article : Google Scholar
|
|
10
|
McQueen AE, Kanamaluru D, Yan K, Gray NE,
Wu L, Li ML, Chang A, Hasan A, Stifler D, Koliwad SK and Wang JC:
The C-terminal fibrinogen-like domain of angiopoietin-like 4
stimulates adipose tissue lipolysis and promotes energy
expenditure. J Biol Chem. 292:16122–16134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tan MJ, Teo Z, Sng MK, Zhu P and Tan NS:
Emerging roles of angiopoietin-like 4 in human cancer. Mol Cancer
Res. 10:677–688. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen JW, Luo YJ, Yang ZF, Wen LQ and Huang
L: Knockdown of angiopoietin like 4 inhibits the development of
human gastric cancer. Oncol Rep. 39:1739–1746. 2018.PubMed/NCBI
|
|
13
|
Tanaka J, Irie T, Yamamoto G, Yasuhara R,
Isobe T, Hokazono C, Tachikawa T, Kohno Y and Mishima K: ANGPTL4
regulates the metastatic potential of oral squamous cell carcinoma.
J Oral Pathol Med. 44:126–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang H, Wei S, Ning S, Jie Y, Ru Y and Gu
Y: Evaluation of TGFβ, XPO4, elF5A2 and ANGPTL4 as biomarkers in
HCC. Exp Ther Med. 5:119–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakayama T, Hirakawa H, Shibata K, Nazneen
A, Abe K, Nagayasu T and Taguchi T: Expression of angiopoietin-like
4 (ANGPTL4) in human colorectal cancer: ANGPTL4 promotes venous
invasion and distant metastasis. Oncol Rep. 25:929–935. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong D, Jia L, Zhou Y, Ren L, Li J and
Zhang J: Serum level of ANGPTL4 as a potential biomarker in renal
cell carcinoma. Urol Oncol. 35:279–285. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Liu LM, Wei L, Ye WW, Meng XY,
Chen F, Xiao Q, Chen JY and Zhou Y: Angiopoietin-like protein 4
improves glucose tolerance and insulin resistance but induces liver
steatosis in high-fat-diet mice. Mol Med Rep. 14:3293–3300. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nitulescu GM, Van De Venter M, Nitulescu
G, Ungurianu A, Juzenas P, Peng Q, Olaru OT, Grădinaru D, Tsatsakis
A, Tsoukalas D, et al: The Akt pathway in oncology therapy and
beyond (Review). Int J Oncol. 53:2319–2331. 2018.PubMed/NCBI
|
|
19
|
Nitulescu GM, Margina D, Juzenas P, Peng
Q, Olaru OT, Saloustros E, Fenga C, Spandidos DA, Libra M and
Tsatsakis AM: Akt inhibitors in cancer treatment: The long journey
from drug discovery to clinical use (Review). Int J Oncol.
48:869–885. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mundi PS, Sachdev J, McCourt C and
Kalinsky K: AKT in cancer: New molecular insights and advances in
drug development. Br J Clin Pharmacol. 82:943–956. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Amin MB, Edge SB, Greene FL, et al: AJCC
cancer staging manual. 8th. Springer; New York, NY: 2017,
View Article : Google Scholar
|
|
22
|
Cazes A, Galaup A, Chomel C, Bignon M,
Bréchot N, Le Jan S, Weber H, Corvol P, Muller L, Germain S and
Monnot C: Extracellular matrix-bound angiopoietin-like 4 inhibits
endothelial cell adhesion, migration, and sprouting and alters
actin cytoskeleton. Circ Res. 99:1207–1215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Galaup A, Cazes A, Le Jan S, Philippe J,
Connault E, Le Coz E, Mekid H, Mir LM, Opolon P, Corvol P, et al:
Angiopoietin-like 4 prevents metastasis through inhibition of
vascular permeability and tumor cell motility and invasiveness.
Proc Natl Acad Sci USA. 103:18721–18726. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
La Paglia L, Listì A, Caruso S, Amodeo V,
Passiglia F, Bazan V and Fanale D: Potential role of ANGPTL4 in the
cross talk between metabolism and cancer through PPAR signaling
pathway. PPAR Res. 2017:81872352017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu J, Jham BC, Ma T, Friedman ER, Ferreira
L, Wright JM, Accurso B, Allen CM, Basile JR and Montaner S:
Angiopoietin-like 4: A novel molecular hallmark in oral Kaposi's
sarcoma. Oral Oncol. 47:371–375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mathieu M, Iampietro M, Chuchana P, Guérit
D, Djouad F, Noël D and Jorgensen C: Involvement of
angiopoietin-like 4 in matrix remodeling during chondrogenic
differentiation of mesenchymal stem cells. J Biol Chem.
289:8402–8412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang Z, Xie J, Lin S, Li S, Huan Z, Wang
Y and Ye J: The downregulation of ANGPTL4 inhibits the migration
and proliferation of tongue squamous cell carcinoma. Arch Oral
Biol. 71:144–149. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ng KT, Xu A, Cheng Q, Guo DY, Lim ZX, Sun
CK, Fung JH, Poon RT, Fan ST, Lo CM and Man K: Clinical relevance
and therapeutic potential of angiopoietin-like protein 4 in
hepatocellular carcinoma. Mol Cancer. 13:1962014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Verine J, Lehmann-Che J, Soliman H,
Feugeas JP, Vidal JS, Mongiat-Artus P, Belhadj S, Philippe J,
Lesage M, Wittmer E, et al: Determination of Angptl4 mRNA as a
diagnostic marker of primary and metastatic clear cell renal-cell
carcinoma. PLoS One. 5:e104212010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ifon ET, Pang AL, Johnson W, Cashman K,
Zimmerman S, Muralidhar S, Chan WY, Casey J and Rosenthal LJ: U94
alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis
of prostate cancer cell line PC3. Cancer Cell Int. 5:192005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wei Z, Shan Y, Tao L, Liu Y, Zhu Z, Liu Z,
Wu Y, Chen W, Wang A and Lu Y: Diallyl trisulfides, a natural
histone deacetylase inhibitor, attenuate HIF-1α synthesis, and
decreases breast cancer metastasis. Mol Carcinog. 56:2317–2331.
2017. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Padua D, Zhang XH, Wang Q, Nadal C, Gerald
WL, Gomis RR and Massagué J: TGFbeta primes breast tumors for lung
metastasis seeding through angiopoietin-like 4. Cell. 133:66–77.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang H, Wong CC, Wei H, Gilkes DM,
Korangath P, Chaturvedi P, Schito L, Chen J, Krishnamachary B,
Winnard PT Jr, et al: HIF-1-dependent expression of
angiopoietin-like 4 and L1CAM mediates vascular metastasis of
hypoxic breast cancer cells to the lungs. Oncogene. 31:1757–1770.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liao YH, Chiang KH, Shieh JM, Huang CR,
Shen CJ, Huang WC and Chen BK: Epidermal growth factor-induced
ANGPTL4 enhances anoikis resistance and tumour metastasis in head
and neck squamous cell carcinoma. Oncogene. 36:2228–2242. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun Y, Long J and Zhou Y:
Angiopoietin-like 4 promotes melanoma cell invasion and survival
through aldolase A. Oncol Lett. 8:211–217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gong X, Hou Z, Endsley MP, Gronseth EI,
Rarick KR, Jorns JM, Yang Q, Du Z, Yan K, Bordas ML, et al:
Interaction of tumor cells and astrocytes promotes breast cancer
brain metastases through TGF-β2/ANGPTL4 axes. NPJ Precis Oncol.
3:242019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tripathy J, Tripathy A, Thangaraju M, Suar
M and Elangovan S: α-Lipoic acid inhibits the migration and
invasion of breast cancer cells through inhibition of TGFβ
signaling. Life Sci. 207:15–22. 2018. View Article : Google Scholar : PubMed/NCBI
|
